1. In Vivo
  2. >>Business Strategy

A Tepid Wedding, Now A Possible Divorce

The year-old union of bioMerieux-Pierre Fabre appears to be on the verge of disintegrating, amid lack of a coherent strategy, disagreements between the two founders who spearheaded the deal, and departure of key top executives. The company won't comment except to say that it is considering various alternatives including a break-up. Unraveling should not be difficult, since the two companies haven't integrated much. And the separation would leave bioMerieux, now the world's eighth largest diagnostics company, and Pierre Fabre, one of France's largest independent pharmaceutical companies, free to seek more appropriate solutions to the challenges they face.

When French newspapers reported in late January that bioMerieux-Pierre Fabre SA was ending its year-old merger, few knowledgeable people were surprised. The union in January 2001 created France's largest independent pharmaceutical company [See Deal]. (See "BioMerieux and Pierre Fabre's Surprise," IN VIVO, October 2000 [A#2000800180.) But the rationale behind it—to better compete in consolidating industries—remained unconvincing.

As the world's eighth largest diagnostics company, bioMerieux SA's expertise has been in infectious diseases. Pierre Fabre SA, one of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.